Literature DB >> 23292955

Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.

Daniel W Vermeer1, William C Spanos, Paola D Vermeer, Annie M Bruns, Kimberly M Lee, John H Lee.   

Abstract

The increasing incidence of human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma (OSSC) demands development of novel therapies. Despite presenting at a more advanced stage, HPV(+) oropharyngeal squamous cell carcinoma (OSCC) have a better prognosis than their HPV(-) counterparts. We have previously demonstrated that clearance of HPV(+) OSCC during treatment with radiation and chemotherapy requires an immune response which is likely responsible for the improved clinical outcomes. To further elucidate the mechanism of immune-mediated clearance, we asked whether radiation therapy induces tumor cell changes that allow the body to recognize and aid in tumor clearance. Here, we describe a radiation-induced change in tumor surface protein expression that is critical for immune-mediated clearance. Radiation therapy decreases surface expression of CD47, a self-marker. CD47 is frequently overexpressed in head and neck squamous cell carcinoma and radiation induces a decrease of CD47 in a dose-dependent manner. We show that both in vitro and in vivo tumor cell CD47 protein levels are restored over time after sublethal radiation exposure and that protein levels on adjacent, normal tissues remain unaffected. Furthermore, reduction of tumor cell CD47 increases phagocytosis of these cells by dendritic cells and leads to increased interferon gamma and granzyme production from mixed lymphocytes. Finally, decreasing tumor cell CD47 in combination with standard radiation and chemotherapy results in improved immune-mediated tumor clearance in vivo. These findings help define an important mechanism of radiation-related immune clearance and suggest that decreasing CD47 specifically on tumor cells may be a good therapeutic target for HPV related disease.
Copyright © 2013 UICC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23292955      PMCID: PMC3972896          DOI: 10.1002/ijc.28015

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

Review 1.  MHC antigens and tumor escape from immune surveillance.

Authors:  F Garrido; I Algarra
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

Review 2.  On the origin and function of immune 'self' recognition.

Authors:  Timo K van den Berg
Journal:  Immunol Lett       Date:  2009-10-04       Impact factor: 3.685

Review 3.  The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions.

Authors:  Federico Garrido; Ignacio Algarra; Angel M García-Lora
Journal:  Cancer Immunol Immunother       Date:  2010-07-13       Impact factor: 6.968

Review 4.  Integrin-associated protein (CD47) and its ligands.

Authors:  E J Brown; W A Frazier
Journal:  Trends Cell Biol       Date:  2001-03       Impact factor: 20.808

5.  Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

Authors:  Mark P Chao; Chad Tang; Russell K Pachynski; Robert Chin; Ravindra Majeti; Irving L Weissman
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

6.  Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation.

Authors:  S Latour; H Tanaka; C Demeure; V Mateo; M Rubio; E J Brown; C Maliszewski; F P Lindberg; A Oldenborg; A Ullrich; G Delespesse; M Sarfati
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

7.  Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.

Authors:  Justin B Maxhimer; David R Soto-Pantoja; Lisa A Ridnour; Hubert B Shih; William G Degraff; Maria Tsokos; David A Wink; Jeff S Isenberg; David D Roberts
Journal:  Sci Transl Med       Date:  2009-10-21       Impact factor: 17.956

Review 8.  Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.

Authors:  Takashi Matozaki; Yoji Murata; Hideki Okazawa; Hiroshi Ohnishi
Journal:  Trends Cell Biol       Date:  2009-01-12       Impact factor: 20.808

9.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

Review 10.  Local control by radiotherapy: is that all there is?

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  Breast Cancer Res       Date:  2008-11-05       Impact factor: 6.466

View more
  43 in total

1.  Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response.

Authors:  C Cleary; J E Leeman; D S Higginson; N Katabi; E Sherman; L Morris; S McBride; N Lee; N Riaz
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-04-01       Impact factor: 4.126

2.  The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.

Authors:  Randall J Kimple; Paul M Harari
Journal:  Ann Transl Med       Date:  2015-05

Review 3.  Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck.

Authors:  Grace C Blitzer; Molly A Smith; Stephen L Harris; Randall J Kimple
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-15       Impact factor: 7.038

Review 4.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

5.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

Authors:  David R Soto-Pantoja; Masaki Terabe; Arunima Ghosh; Lisa A Ridnour; William G DeGraff; David A Wink; Jay A Berzofsky; David D Roberts
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

6.  Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein.

Authors:  Yuanhong Zheng; Fangyuan Zou; Jingjing Wang; Guifang Yin; Vanminh Le; Zhewei Fei; Jianwen Liu
Journal:  J Biol Chem       Date:  2015-02-19       Impact factor: 5.157

7.  Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.

Authors:  Falguni Parikh; Dorothée Duluc; Naoko Imai; Amelia Clark; Krzys Misiukiewicz; Marcello Bonomi; Vishal Gupta; Alexis Patsias; Michael Parides; Elizabeth G Demicco; David Y Zhang; Seunghee Kim-Schulze; Johnny Kao; Sacha Gnjatic; Sangkon Oh; Marshall R Posner; Andrew G Sikora
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

8.  Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy.

Authors:  M Vatca; J T Lucas; J Laudadio; R B D'Agostino; J D Waltonen; C A Sullivan; R Rouchard-Plasser; M Matsangou; J D Browne; K M Greven; M Porosnicu
Journal:  Oral Oncol       Date:  2014-07-03       Impact factor: 5.337

Review 9.  Oropharyngeal squamous cell carcinoma treatment: current standards and future directions.

Authors:  Shanthi Marur; Barbara Burtness
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

Review 10.  Is radiation dose reduction the right answer for HPV-positive head and neck cancer?

Authors:  Randall J Kimple; Paul M Harari
Journal:  Oral Oncol       Date:  2013-10-14       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.